In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Aphton acquires igeneon for $74mm in stock

Executive Summary

Aphton Corp. (immunotherapies for cancer and other diseases) has entered into a definitive agreement to acquire privately held igeneon AG (cancer therapeutics). Igeneon shareholders will receive 21.5mm shares of Aphton's stock for all of the company's outstanding equity; based on Aphton's pre-announcement market average price, the deal is valued at about $74mm.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies